Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cosmo Bio Co's Enterprise Value is 円4,519 Mil.
Cosmo Bio Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was 円504 Mil. Therefore, Cosmo Bio Co's EV-to-EBIT ratio for today is 8.97.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Cosmo Bio Co's Enterprise Value is 円4,519 Mil.
Cosmo Bio Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was 円671 Mil. Therefore, Cosmo Bio Co's EV-to-EBITDA ratio for today is 6.73.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Cosmo Bio Co's Enterprise Value is 円4,519 Mil.
Cosmo Bio Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was 円10,766 Mil. Therefore, Cosmo Bio Co's EV-to-Revenue ratio for today is 0.42.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Cosmo Bio Co's Enterprise Value is 円4,519 Mil.
Cosmo Bio Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was 円314 Mil. Therefore, Cosmo Bio Co's EV-to-FCF ratio for today is 14.39.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Cosmo Bio Co (TSE:3386) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Cosmo Bio Co's current Enterprise Value is 円4,519 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Cosmo Bio Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was 円504 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Cosmo Bio Co's current Enterprise Value is 円4,519 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Cosmo Bio Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was 円671 Mil.
Cosmo Bio Co's current Enterprise Value is 円4,519 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Cosmo Bio Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was 円10,766 Mil.
Cosmo Bio Co's current Enterprise Value is 円4,519 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Cosmo Bio Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was 円595 Mil.
Cosmo Bio Co's current Enterprise Value is 円4,519 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Cosmo Bio Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was 円314 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo Bio Co Enterprise Value Related Terms
Cosmo Bio Co Enterprise Value Historical Data
* Premium members only.
The historical data trend for Cosmo Bio Co's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3386 vs TMO, DHR, IDXX: Enterprise Value Comparison
For the Diagnostics & Research subindustry, Cosmo Bio Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo Bio Co Enterprise Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cosmo Bio Co's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Cosmo Bio Co's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Cosmo Bio Co's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo Bio Co (TSE:3386) has a Enterprise Value of 円4,519 Mil as of Jul. 09, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Cosmo Bio Co and its competitors.
Is Cosmo Bio Co's Enterprise Value too high?
Cosmo Bio Co's current Enterprise Value is 円4,519 Mil. Overall, Cosmo Bio Co has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cosmo Bio Co's Enterprise Value compare to TMO and DHR?
Cosmo Bio Co's Enterprise Value of 円4,519 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Diagnostics & Research company?
A good Enterprise Value depends on the Medical Diagnostics & Research industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Cosmo Bio Co and its competitors. Cosmo Bio Co's current Enterprise Value is 円4,519 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo Bio Co stock overvalued right now?
Based on GuruFocus' analysis, Cosmo Bio Co (TSE:3386) is currently considered Fairly Valued. The stock's GF Value™ is 円1,246.90, compared to a current price of 円1,262.00 — trading 1.2% above its estimated fair value. The current Enterprise Value is 円4,519 Mil. Cosmo Bio Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Cosmo Bio Co (TSE:3386), the current Enterprise Value is 円4,519 Mil as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo Bio Co (TSE:3386) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo Bio Co stock appears to be overvalued.
The current stock price of 円1,262.00 is trading 1.2% above its estimated GF Value™ of 円1,246.90.
GuruFocus considers Cosmo Bio Co to be Fairly Valued.
Key valuation signals for TSE:3386:
Enterprise Value: 円4,519 Mil
GF Value™: 円1,246.90 vs. price of 円1,262.00 (1.2% above fair value)
No single metric tells the full story. See the TSE:3386 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo Bio Co Ltd is a diagnostic and research company based in Japan. The business of the company includes the purchase of reagents, instruments, and clinical test drugs for research in life science and domestic sales.
73GF Score
Get the complete analysis for TSE:3386
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3386 has been successfully added to your 
